All NewsPractice Management
All VideosExpert InterviewsPodcastsMedical World NewsViewpointsInsightsCase Based Roundtable SeriesCase StudiesCase of the QuarterPractice OwnershipRapid ReadoutWhat’s Your WhEYE?
Conference CoverageConference ListingConference Recaps
Blog
Digital EditionSupplements And Featured PublicationsiTech
Partners
Job BoardSponsored
SubscribeCE
AMD
Allergy
Blepharitis
COVID-19
Cataract
Comanagement
Comprehensive Eye Exams
Conjunctivitis
Contact Lenses
Cornea
DME
Diabetic Eye Disease
Dry Eye
Geographic Atrophy
Glasses
Glaucoma
LASIK
Lens Technology
Lid and Lash
Myopia
Nutrition
OCT
Ocular Surface Disease
Optic Relief
Patient Care
Pediatrics
Presbyopia
Ptosis
Refractive Surgery
Retina
Technology
Therapeutic Cataract & Refractive
Spotlight -
  • Geographic Atrophy
  • Myopia
EyeCare Network
  • Ophthalmology Times

  • Modern Retina

  • Optometry Times

  • Ophthalmology Times Europe

AMD
Allergy
Blepharitis
COVID-19
Cataract
Comanagement
Comprehensive Eye Exams
Conjunctivitis
Contact Lenses
Cornea
DME
Diabetic Eye Disease
Dry Eye
Geographic Atrophy
Glasses
Glaucoma
LASIK
Lens Technology
Lid and Lash
Myopia
Nutrition
OCT
Ocular Surface Disease
Optic Relief
Patient Care
Pediatrics
Presbyopia
Ptosis
Refractive Surgery
Retina
Technology
Therapeutic Cataract & Refractive
EyeCare Network
  • Ophthalmology Times

  • Modern Retina

  • Optometry Times

  • Ophthalmology Times Europe

    • Blog
    • Partners
    • Subscribe
    • CE
Advertisement

A different approach to treating demodex blepharitis

January 3, 2014
By Katherine M. Mastrota, MS, OD, FAAO, Dipl ABO
Article

You see them year after year in your chair: persistent cylindrical dandruff (CD), red lid margins, and eyelash distention. You've prescribed lid scrubs with baby shampoo, warm compresses, and even steroid/antibiotic combo drops, but nothing seems to resolve the condition. If this is the case, it's likely you are dealing with demodex blepharitis.

You see them year after year in your chair: persistent cylindrical dandruff (CD), red lid margins, and eyelash distention. You've prescribed lid scrubs with baby shampoo, warm compresses, and even steroid/antibiotic combo drops, but nothing seems to resolve the condition. If this is the case, it's likely you are dealing with demodex blepharitis. Research indicates that demodex is present in all, or at least most, cases of anterior blepharitis.1

Studies have shown that cylindrical dandruff is pathognomic for demodex,1,2 while conventional wisdom holds that blepharitis is staphylococcal or sebhorreic.3 This represents a paradigm shift and requires a different approach to treatment.

While the aforementioned conventional treatment options can clean up the mess and decrease some signs of blepharitis, none are toxic to demodex, and the condition will persist.4 While new treatments under consideration include topical or oral ivermectin and Greenbug for People cedar oil, a new treatment paradigm is taking shape, and tea tree oil is at the heart of it.

Related: Diagnosing demodex

Left untreated, or poorly managed, chronic blepharitis has many adverse effects-it causes allergy, inflammation, lash loss and misdirection, telangiectasia, and may play a role in meibomian gland dysfunction.5

Demodex blepharitis is nothing new. Interest has waxed and waned over the years, and a landmark paper on demodex was produced by an ophthalmologist in 1967.6 He lamented the fact that he had overlooked demodex for over 30 years! Most eyecare practitioners have overlooked demodex as well.

Next: Before starting treatment

 

Before starting treatment

Some things to consider before initiating treatment:

• Anterior segment photographs are useful to monitor progress and to educate patients.

• You can epilate lashes and show the mites to your patients, which should increase treatment compliance.

• Consider using an allergy survey, such as total ocular symptoms score (TOSS) to monitor subjective improvement.

• Because macadamia nut oil will be used in-office, ask about nut allergies.

Related: Overview of demodex

It is important to set expectations and educate patients. I explain that demodex is a ubiquitous mite. All adults have some mites, but if we see blepharitis, they simply have too many. In fact, recent analysis of 100 consecutive patients in my practice showed more than 25 had demodex blepharitis confirmed with a microscope. The goal of the treatment is to decrease, not eradicate, the mite population. Tell patients that demodex is a chronic but manageable condition. Long-term eyelid hygiene will be required.

I classify patients as mild, moderate, or severe based on quantity of cylindrical dandruff (CD). I use a relative scale of 0-3:

• 1 is mild, with CD present on fewer than 5 lashes

• 2 is moderate, with CD present on 5-9 lashes

• 3 is severe, with CD present on 10 or more lashes.

You may develop your own scale. I treat patients based on signs, not symptoms.

Next: Treatment

 


Treatment

My current, but evolving, treatment algorithm is based on the advice of Mario Gutierrez, OD, of San Antonio, TX.7

Mild cases are prescribed at-home treatments that involve tea tree oil lid wipes twice a day and tea tree oil shampoo and facial wash. Cliradex by Bio-Tissue is currently my lid wipe of choice. Moderate to severe patients are treated weekly in-office with tea tree oil for 3 consecutive weeks at a minimum and use tea tree oil lid wipes twice per day at home. In addition, every 3-6 months I treat severe patients with Rysurg’s new BlephEx device (see “New products help provide treatment”).

Related: Treating demodex

Tea tree oil lid wipes can have an intense sensation that diminishes over time. I advise my patients to think  of a cooling vs. a burning sensation. We demonstrate this in-office, so patients know what to expect. Patients are instructed to use the wipes on the eyelashes, forehead, eyebrows, and cheeks because the mites live in these places as well.

This is my in-office treatment protocol:

• Testravisc (tetracaine, Ocusoft) drops are applied prior to treatment.

• Sit the patient behind the slit lamp.

• With the patient looking away from the lid you are working on, use a cotton swab to apply a 50-50 mixture of tea tree oil and macadamia nut oil to the base of the eyelashes. Try to loosen the CD.

• Control the lid with one hand, and apply the tea tree oil mix with the other, being careful to avoid the cornea.

• The patient should sit with his eyes closed for 10 minutes.

• Reapply the mixture and have the patient sit with closed eyes for another 10 minutes.

• Rinse the patient’s eyes thoroughly.

I reassess all patients after 1 month. Some patients, especially those with dense eyelashes or heavy CD, may require more treatments. Once the blepharitis is under control, patients are continued on tea tree oil lid wipes at home on daily basis and followed in 2-3 months.

All patients are given information sheets about blepharitis as well as homework, such as discarding makeup, using hot water, and drying linens on the high dryer setting. Family members should also be evaluated, and treated if needed, for demodex.

Due to recent dermatological research showing a link between demodex and rosacea,8 the mite has once again come into the spotlight. I have found that diagnosing and treating these patients has them looking and feeling better. Many treated patients have commented that their eyes haven't felt this good in a long time.

Want more info on demodex? Click here!

 

 

More on demodex: Treat rosacea by treating the cause-demodex

A different approach to treating demodex blepharitis

References

1. Gao Y-Y, Di Pascuale MA, Li W, Liu DT, et al. High prevalence of ocular Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3089-94.

2. De Venecia AB, Siong RLB. Demodex sp. Infestation in anterior blepharitis, meibomian-gland dysfunction, and mixed blepharitis. Phillipine J Ophthalmol. 2001 Jan-June;36(1):15-22.

3. Benitez-del-castillo JM, Lemp MA. Anterior blepharitis. Ocular Surface Disorders. JP Medical Publishers. 2013:133.

4. Leibowitz HM, Capino D. Treatment of chronic blepharitis. Arch Ophthalmol. 1988 Jun;106(6):720.

5. Horwath-Winter J, Rabensteiner DF, Schwantzer G, Bolden I, et al. The lid margin and Demodex. Acta Ophthalmologica. 2012;90(249):0

6. Coston TO. Demodex folliculorum blepharitis. Trans Am Ophthalmol Soc. 1967;65:361-92.

7. Gutierrez M. Demodex infestation requires immediate, aggressive treatment by doctor, patient. PCON. 2011 June;17(6).

8. Jarmuda S, O’Reilly N, Zaba R, Jakubowicz O, et al. Potential role of Demodex mites and bacteria in the induction of rosacea. J Med Microbiol. 2012 Nov;61(Pt 11):1504-10.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Subscribe Now!
Recent Videos
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
What's Your WhEYE? A conversation with Ali Tafreshi, CEO and president of Topcon
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, ponders what she would like to see develop as both a researcher and a clinician in the dry eye space.
What's on the clinical wishlist for dry eye with Dr Bridgitte Shen Lee
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, details the key takeaways from a poster presentation she participated in during ARVO 2025.
ARVO 2025: Miebo demonstrates favorable tolerability in prescription refill rates
Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.
ARVO 2025: The early adoption and utilization of perfluorohexoloctane (Miebo)
Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
A sneak peek into the Collaborative Care Symposium 2025 with Steven Greenstein, MD
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
ARVO 2025: Dr Julie Poteet reviews patient-reported outcomes following use of Blink Triple Care
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
ARVO 2025: Lens thickness as a significant biomarker for accommodation in presbyopia
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
ARVO 2025: OCT-based marker for accommodative effort in presbyopes
Karl Stonecipher ASCRS 2025
Q&A with Karl Stonecipher, MD, on outcomes of LASIK using the Teneo platform to correct high myopia
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Predicting presbyopia reading ADD and progression with AI and machine learning algorithm
Related Content
Advertisement
Swept source anterior segment OCT aids in early diagnosis of childhood glaucoma. - Image credit: ©Serhii—stock.adobe.com

Swept-source anterior segment-OCT aids in early diagnosis of childhood glaucoma

Lynda Charters
May 30th 2025
Article
New Opportunities in Topical Glaucoma Management

New Opportunities in Topical Glaucoma Management

Mitch Ibach, OD, FAAO;Jessica Steen, OD, FAAO
January 31st 2025
Podcast
Closeup of dry eye before and after treatment. Image credit: AdobeStock/AlessandroGrandini

Iolyx Therapeutics releases phase 2 results for ILYX-002 in autoimmune-associated dry eye disease

Martin David Harp, Editor, Ophthalmology Times
May 29th 2025
Article
You and Eye: Vision training research in eSports - with Tiffany Tsoi, OD, FAAO

You and Eye: Vision training research in eSports - with Tiffany Tsoi, OD, FAAO

Miriam Korik, OD;Tiffany Tsoi, OD;Emily Kaiser Maharjan, Assistant Managing Editor
December 4th 2024
Podcast
Collaborative Care Symposium cochairs Gelles and Greenstein preview the 2025 meeting

Bridging disciplines and elevating care: A Q&A with John Gelles, OD, and Steven Greenstein, MD

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA;Steven A. Greenstein, MD;Emily Kaiser Maharjan, Assistant Managing Editor
May 28th 2025
Article
Doctor pushing button on AI graphic Image credit: AdobeStock/Toowongsa

AI therapy planning support assistant launched by deepeye Medical receives CE mark

Jordana Joy, Associate Editor
May 28th 2025
Article
Related Content
Advertisement
Swept source anterior segment OCT aids in early diagnosis of childhood glaucoma. - Image credit: ©Serhii—stock.adobe.com

Swept-source anterior segment-OCT aids in early diagnosis of childhood glaucoma

Lynda Charters
May 30th 2025
Article
New Opportunities in Topical Glaucoma Management

New Opportunities in Topical Glaucoma Management

Mitch Ibach, OD, FAAO;Jessica Steen, OD, FAAO
January 31st 2025
Podcast
Closeup of dry eye before and after treatment. Image credit: AdobeStock/AlessandroGrandini

Iolyx Therapeutics releases phase 2 results for ILYX-002 in autoimmune-associated dry eye disease

Martin David Harp, Editor, Ophthalmology Times
May 29th 2025
Article
You and Eye: Vision training research in eSports - with Tiffany Tsoi, OD, FAAO

You and Eye: Vision training research in eSports - with Tiffany Tsoi, OD, FAAO

Miriam Korik, OD;Tiffany Tsoi, OD;Emily Kaiser Maharjan, Assistant Managing Editor
December 4th 2024
Podcast
Collaborative Care Symposium cochairs Gelles and Greenstein preview the 2025 meeting

Bridging disciplines and elevating care: A Q&A with John Gelles, OD, and Steven Greenstein, MD

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA;Steven A. Greenstein, MD;Emily Kaiser Maharjan, Assistant Managing Editor
May 28th 2025
Article
Doctor pushing button on AI graphic Image credit: AdobeStock/Toowongsa

AI therapy planning support assistant launched by deepeye Medical receives CE mark

Jordana Joy, Associate Editor
May 28th 2025
Article
Advertisement
Recent Content
Swept source anterior segment OCT aids in early diagnosis of childhood glaucoma. - Image credit: ©Serhii—stock.adobe.com

Swept-source anterior segment-OCT aids in early diagnosis of childhood glaucoma

Four hands putting together puzzle pieces Image credit: AdobeStock/Johnstocker

Pangaea Data and Topcon Healthcare announce strategic investment

Closeup of dry eye before and after treatment. Image credit: AdobeStock/AlessandroGrandini

Iolyx Therapeutics releases phase 2 results for ILYX-002 in autoimmune-associated dry eye disease

FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease

FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease

View More Recent Content
Advertisement
Advertisement
x
Advertise
About Us
Editorial
Contact Us
Job Board
Terms & Conditions
Privacy
Do not sell my Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.